top of page
  • EVI

Latest results from EVI-led projects ShigEtecVax and ShigaPlexIM to be presented at the VASE 2022

29 November 2022

The Vaccines Against Shigella and ETEC (VASE) Conference is an international gathering dedicated to developing Shigella and enterotoxigenic Escherichia coli (ETEC) vaccines. Hosted by PATH, a global non-profit organisation dedicated to achieving health equity, it’s an event for people like you who care about improving public health and saving lives by reducing diarrheal disease.

The latest results from two projects coordinated by EVI will be presented at the VASE conference 2022 to be held in Washington on 29 November–01 December 2022: ShigEtecVax funded by the European Commission under the Horizon 2020 Framework Programme and ShigaPlexIM funded by European & Developing Countries Clinical Trials Partnership (EDCTP2) Programme. Dr Aicha Sayeh is representing EVI.

For the ShigEtecVax project, the safety and immunogenicity data of a combined Shigella/ETEC live attenuated vaccine candidate that was tested in a phase Ia clinical trial in Hungary will be presented by Eveliqure Biotechnologies Gmbh. Based on these encouraging results, a phase Ib trial in the endemic population in Bangladesh is being prepared by the project partners.

Four additional posters will present the epidemiological baseline studies that were conducted in the context of the ShigaPlexIM project at Groupe de Recherche Action en Santé (GRAS, Burkina Faso) and Centre for Infectious Disease Research in Zambia (CIDRZ, Zambia). These studies aimed at assessing the prevalence of Shigella and other enteric bacterial infections in children under five presenting with Severe-to-Moderate Diarrhoea (SMD). The results of this study will support the design of future efficacy trials for Shigella vaccine candidates.

The ShigaPlexIM is part of the EDCTP2 Programme supported by the European Union (RIA2018V-2308)

The ShigEtecVax project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568


bottom of page